VRTX Vertex Pharmaceuticals Inc
Price (delayed)
$484.24
Market cap
$124.35B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.08
Enterprise value
$121.44B
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather
Highlights
VRTX's revenue is up by 12% YoY and by 3.7% QoQ
The gross profit has grown by 10% YoY and by 3.7% from the previous quarter
VRTX's debt has soared by 129% YoY but it is down by 2.7% QoQ
Vertex Pharmaceuticals's quick ratio has decreased by 40% YoY but it has increased by 4.3% QoQ
The EPS has dropped by 115% year-on-year and by 12% since the previous quarter
Vertex Pharmaceuticals's net income has shrunk by 115% YoY and by 12% QoQ
Key stats
What are the main financial stats of VRTX
Market
Valuations
Earnings
Shares outstanding
256.79M
Market cap
$124.35B
Enterprise value
$121.44B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.6
Price to sales (P/S)
11.33
EV/EBIT
435.1
EV/EBITDA
249.71
EV/Sales
11.02
Revenue
$11.02B
Gross profit
$9.49B
Operating income
-$233.4M
Net income
-$535.6M
EBIT
$279.1M
EBITDA
$486.3M
Free cash flow
-$790.3M
Per share
Balance sheet
Liquidity
EPS
-$2.08
EPS diluted
-$2.08
Free cash flow per share
-$3.06
Book value per share
$63.72
Revenue per share
$42.73
TBVPS
$79.95
Total assets
$22.53B
Total liabilities
$6.12B
Debt
$1.66B
Equity
$16.41B
Working capital
$6.03B
Debt to equity
0.1
Current ratio
2.69
Quick ratio
2.17
Net debt/EBITDA
-5.99
Margins
Efficiency
Dividend
EBITDA margin
4.4%
Gross margin
86.1%
Net margin
-4.9%
Operating margin
-2.1%
Return on assets
-2.4%
Return on equity
-3.3%
Return on invested capital
2.3%
Return on capital employed
1.5%
Return on sales
2.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRTX stock price
How has the Vertex Pharmaceuticals stock price performed over time
Intraday
0.81%
1 week
5.5%
1 month
13.17%
1 year
15.4%
YTD
20.25%
QTD
20.25%
Financial performance
How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$11.02B
Gross profit
$9.49B
Operating income
-$233.4M
Net income
-$535.6M
Gross margin
86.1%
Net margin
-4.9%
Vertex Pharmaceuticals's net income has shrunk by 115% YoY and by 12% QoQ
VRTX's net margin has shrunk by 113% YoY and by 9% QoQ
The operating income has dropped by 106% year-on-year but it has grown by 27% since the previous quarter
The operating margin has shrunk by 105% YoY but it has increased by 30% QoQ
Growth
What is Vertex Pharmaceuticals's growth rate over time
Valuation
What is Vertex Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.6
P/S
11.33
EV/EBIT
435.1
EV/EBITDA
249.71
EV/Sales
11.02
The EPS has dropped by 115% year-on-year and by 12% since the previous quarter
The stock's price to book (P/B) is 15% more than its 5-year quarterly average of 6.6 and 9% more than its last 4 quarters average of 7.0
The equity has contracted by 7% YoY but it has grown by 5% from the previous quarter
The price to sales (P/S) is 17% more than the 5-year quarterly average of 9.7 and 4.9% more than the last 4 quarters average of 10.8
VRTX's revenue is up by 12% YoY and by 3.7% QoQ
Efficiency
How efficient is Vertex Pharmaceuticals business performance
The return on equity has dropped by 115% year-on-year and by 14% since the previous quarter
VRTX's return on assets has dropped by 114% year-on-year and by 9% since the previous quarter
The return on invested capital has dropped by 97% year-on-year and by 21% since the previous quarter
The return on sales has dropped by 94% year-on-year and by 11% since the previous quarter
Dividends
What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRTX.
Financial health
How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's quick ratio has decreased by 40% YoY but it has increased by 4.3% QoQ
Vertex Pharmaceuticals's current ratio has decreased by 33% YoY but it has increased by 9% from the previous quarter
VRTX's debt is 90% lower than its equity
The debt to equity has soared by 150% YoY but it fell by 9% QoQ
VRTX's debt has soared by 129% YoY but it is down by 2.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.